Inflammatory Triple-Negative Breast Cancer: Immediate Neoadjuvant Chemoimmunotherapy
For inflammatory triple-negative breast cancer, initiate neoadjuvant pembrolizumab combined with carboplatin and paclitaxel, followed by pembrolizumab with cyclophosphamide and doxorubicin or epirubicin, then proceed to modified radical mastectomy and postmastectomy radiation. 1
Treatment Algorithm
Step 1: Neoadjuvant Systemic Therapy (Category 1)
The current standard of care for stage II-III triple-negative breast cancer, which includes inflammatory presentations, follows the KEYNOTE-522 regimen 1:
- Pembrolizumab + carboplatin + paclitaxel (initial phase)
- Followed by pembrolizumab + cyclophosphamide + doxorubicin or epirubicin
- Continue with adjuvant pembrolizumab after surgery
This regimen achieved 65% pathologic complete response (pCR) rates in the KEYNOTE-522 trial 1. The international consensus mandates that all inflammatory breast cancer patients receive anthracycline and taxane-based chemotherapy 2.
Step 2: Definitive Surgery
After completing neoadjuvant therapy:
- Modified radical mastectomy is the only acceptable surgical approach 2
- Breast-conserving surgery is contraindicated in inflammatory breast cancer
- Immediate reconstruction is not recommended; delayed reconstruction may be considered 2
Step 3: Postmastectomy Radiation
Radiation is mandatory and should be escalated to 66 Gy if the patient meets any of these criteria 2:
- Age >45 years
- Close or positive surgical margins
- Four or more positive lymph nodes after neoadjuvant treatment
- Poor response to neoadjuvant therapy
Step 4: Adjuvant Therapy Based on Residual Disease
If residual disease remains after neoadjuvant therapy:
- Capecitabine for patients who received taxane, alkylator, and anthracycline-based chemotherapy 1
If germline BRCA1/2 mutation is present:
- Olaparib 1
Critical Considerations
Anthracycline-Free Alternative
An anthracycline-free regimen (docetaxel/carboplatin/pembrolizumab) exists but is not recommended for inflammatory breast cancer with lymph node involvement 1. The KEYNOTE-522 regimen with anthracyclines achieved higher pCR rates (65% vs 58%) and is particularly superior in node-positive disease 1.
Prognosis Reality
Despite aggressive multimodal therapy, inflammatory triple-negative breast cancer carries a significantly worse prognosis than non-inflammatory locally advanced disease, with 2-year and 5-year overall survival of only 34% and 26%, respectively 3. Even with complete radiographic response to chemoimmunotherapy, recurrence can occur rapidly 4.
Diagnostic Confirmation Requirements
Before initiating treatment, ensure 2:
- Core biopsy confirming invasive carcinoma
- Skin punch biopsy (at least two specimens) to document dermal lymphovascular invasion
- Confirmation of triple-negative status (ER-, PR-, HER2-)
- Systemic staging with CT and bone scan
Common Pitfalls to Avoid
Do not delay systemic therapy for surgery – Primary systemic chemotherapy is the initial treatment, not surgery 2.
Do not use breast-conserving surgery – Modified radical mastectomy is mandatory regardless of response to neoadjuvant therapy 2.
Do not omit pembrolizumab – The addition of immunotherapy to chemotherapy is now category 1 evidence for stage II-III triple-negative breast cancer 1.
Do not substitute the KEYNOTE-522 regimen with anthracycline-free alternatives in inflammatory disease, especially with nodal involvement, as efficacy is likely inferior 1.